TT 223 + Glucagon-like peptide-1 analogue

Drug Profile

TT 223 + Glucagon-like peptide-1 analogue

Alternative Names: G1 + GLP-1; TT-223 + GLP-1; TT-223 + LY2428757

Latest Information Update: 27 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transition Therapeutics
  • Developer Eli Lilly; Transition Therapeutics
  • Class Antihyperglycaemics; Gastrointestinal hormones; Glucagon-like peptides; Neuropeptides; Peptide hormones
  • Mechanism of Action Gastrin stimulants; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Puerto Rico (SC)
  • 17 Sep 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
  • 25 Mar 2009 Eli Lilly and Transition Therapeutics dose the first patient in a phase Ib study of TT 223 in combination with LY 2428757
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top